maytansine and Meningeal-Neoplasms

maytansine has been researched along with Meningeal-Neoplasms* in 1 studies

Other Studies

1 other study(ies) available for maytansine and Meningeal-Neoplasms

Article	Year
Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: new directions for systemic therapy - a case report and literature review. BMC cancer, 2018, 01-25, Volume: 18, Issue:1 Herein, we report a complete response after whole brain radiotherapy (WBRT) and concomitant T-DM1 in a patient with HER2-positive metastatic breast cancer (MBC) and extensive brain and leptomeningeal involvement.. A 46 years old Caucasian woman with HER2-positive MBC and no baseline CNS involvement, started in August 2015 1. To the best of our knowledge, this is the first case reporting interesting antitumor activity of T-DM1 and concomitant WBRT in both brain and leptomeningeal metastases, with a favorable safety profile and prolonged extracranial disease control. Further prospective studies should confirm these findings. Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Combined Modality Therapy; Docetaxel; Female; Humans; Maytansine; Meningeal Neoplasms; Middle Aged; Receptor, ErbB-2; Taxoids; Trastuzumab	2018

Article

Year

Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: new directions for systemic therapy - a case report and literature review.

BMC cancer, 2018, 01-25, Volume: 18, Issue:1

Herein, we report a complete response after whole brain radiotherapy (WBRT) and concomitant T-DM1 in a patient with HER2-positive metastatic breast cancer (MBC) and extensive brain and leptomeningeal involvement.. A 46 years old Caucasian woman with HER2-positive MBC and no baseline CNS involvement, started in August 2015 1. To the best of our knowledge, this is the first case reporting interesting antitumor activity of T-DM1 and concomitant WBRT in both brain and leptomeningeal metastases, with a favorable safety profile and prolonged extracranial disease control. Further prospective studies should confirm these findings.

Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Combined Modality Therapy; Docetaxel; Female; Humans; Maytansine; Meningeal Neoplasms; Middle Aged; Receptor, ErbB-2; Taxoids; Trastuzumab

2018